CoChat
Sign Up
Cited by 11

The DOI matches its Crossref record.

What’s new in musculoskeletal oncology

Errani, Costantino, Mavrogenis, Andreas F., Tsukamoto, Shinji·2021·BMC Musculoskeletal Disorders
DOI 10.1186/s12891-021-04590-1PMC PMC8369444
Open this paper in CoChat — free account

Abstract

We reviewed the recent literature related to primary musculoskeletal tumors and metastatic bone tumors. With regard to primary bone tumors, computer navigation systems and three-dimensional-printed prostheses seem to be new treatment options, especially in challenging anatomical locations, such as the sacrum and pelvis. Regarding the treatment of giant cell tumor of bone, recent studies have suggested that denosumab administration is related to a higher local recurrence rate following curettage, but a lower local recurrence rate following en bloc resection. In addition, there was no difference in the local recurrence rate at five years after surgery between short-term and long-term denosumab therapy. With regard to soft tissue tumors, percutaneous cryoablation appears to be a new treatment option for extra-abdominal desmoid tumors, with encouraging results. Regarding soft tissue sarcomas, a negative surgical margin of < 1 mm is sufficient to control local recurrence. Pexidartinib seems to be a promising systemic therapy for the treatment of tenosynovial giant cell tumors for which surgery is not expected to improve the function of the affected limb. Finally, the life expectancy of patients is the most important factor in determining the optimal surgical procedure for patients with impending or pathological fractures of the long bone due to metastatic bone tumors. Elevated C-reactive protein level was found to be an independent poor prognostic factor at 1 year after surgery for long bone metastases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12891-021-04590-1

Cites

Statistics

Figures

Fig. 1 The treatment algorithm for giant cell tumor of bone. GCTB: giant cell tumor of bone
Fig. 1 The treatment algorithm for giant cell tumor of bone. GCTB: giant cell tumor of boneCC BY · PubMed Central
Fig. 2 The treatment algorithm for desmoid tumors. PFS: progression-free survival
Fig. 2 The treatment algorithm for desmoid tumors. PFS: progression-free survivalCC BY · PubMed Central
Fig. 3 The treatment algorithm for bone metastases of the extremities
Fig. 3 The treatment algorithm for bone metastases of the extremitiesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 68

  1. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901–8. · DOI
  2. Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Eur J Cancer. 2017;76:118–24. · DOI
  3. Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SPD, Pienkowski A, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015;22:2860–8. · DOI
  4. Tsukamoto S, Tanaka Y, Mavrogenis AF, Kido A, Kawaguchi M, Errani C. Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review. Clin Orthop Relat Res. 2020;478:1076–85. · DOI
  5. Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, et al. Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am. 2018;100:496–504. · DOI
  6. Mak IWY, Evaniew N, Popovic S, Tozer R, Ghert M. A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am. 2014;96:e127. · DOI
  7. Traub F, Singh J, Dickson BC, Leung S, MohanKumar R, Blackstein ME, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer. 2016;59:1–12. · DOI
  8. Medellin MR, Fujiwara T, Tillman RM, Jeys LM, Gregory J, Stevenson JD, et al. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone Joint J. 2018;100–B:1626–32. · DOI
  9. Boriani S, Cecchinato R, Cuzzocrea F, Bandiera S, Gambarotti M, Gasbarrini A. Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal. Preliminary report. Eur Spine J. 2020;29:257–71. · DOI
  10. Hindiskere S, Errani C, Doddarangappa S, Ramaswamy V, Rai M, Chinder PS. Is a short-course of preoperative denosumab as effective as prolonged therapy for giant cell tumor of bone? Clin Orthop Relat Res. 2020;478:2522–33. · DOI
  11. Guo W, Sun X, Zang J, Qu H. Intralesional excision versus wide resection for giant cell tumor involving the acetabulum: Which is better? Clin Orthop Relat Res. 2012;470:1213–20. · DOI
  12. Ruggieri P, Mavrogenis AF, Ussia G, Angelini A, Papagelopoulos PJ, Mercuri M. Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor. Clin Orthop Relat Res. 2010;468:2954–61. · DOI
  13. Thangaraj R, Grimer RJ, Carter SR, Stirling AJ, Spilsbury J, Spooner D. Giant cell tumour of the sacrum: A suggested algorithm for treatment. Eur Spine J. 2010;19:1189–94. · DOI
  14. Zhao Y, Tang X, Yan T, Ji T, Yang R, Guo W. Risk factors for the local recurrence of giant cell tumours of the sacrum treated with nerve-sparing surgery. Bone Joint J. 2020;102–B:1392–8. · DOI
  15. Sambri A, Medellin MR, Errani C, Campanacci L, Fujiwara T, Donati D, et al. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection? J Orthop Sci. 2020;25:513–9. · DOI
  16. Puri A, Gupta SM, Gulia A, Shetty N, Laskar S. Giant cell tumors of the sacrum: Is non-operative treatment effective? Eur Spine J. 2020. https://doi.org/10.1007/s00586-020-06650-x. · DOI
  17. Boriani S, Bandiera S, Casadei R, Boriani L, Donthineni R, Gasbarrini A, et al. Giant cell tumor of the mobile spine: A review of 49 cases. Spine (Phila Pa 1976). 2012;37:E37–45. · DOI
  18. Tsukamoto S, Ciani G, Mavrogenis AF, Ferrari C, Akahane M, Tanaka Y, et al. Outcome of lung metastases due to bone giant cell tumor initially managed with observation. J Orthop Surg Res. 2020;15:510. · DOI
  19. Law GW, Yeo NEM, Howe TS, Tan YZ, Tan SB, Siddiqui MMA. Recommencement of denosumab for unresectable giant cell tumor of the cervical spine: A case report. Spine (Phila Pa 1976). 2018;43:E551–6. · DOI
  20. Raimondi A, Simeone N, Guzzo M, Maniezzo M, Collini P, Morosi C, et al. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review. ESMO Open. 2020;5(4):e000663. https://doi.org/10.1136/esmoopen-2019-000663. · DOI
  21. Liu W, Chan CM, Gong L, Bui MM, Han G, Letson GD, et al. Malignancy in giant cell tumor of bone in the extremities. J Bone Oncol. 2021;26:100334. · DOI
  22. Anract P, De Pinieux G, Cottias P, Pouillart P, Forest M, Tomeno B. Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: A review of 29 cases. Int Orthop. 1998;22:19–26. · DOI
  23. Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer. 2003;97:2520–9. · DOI
  24. Zhang KX, Chai W, Zhao JJ, Deng JH, Peng Z, Chen JY. Comparison of three treatment methods for simple bone cyst in children. BMC Musculoskelet Disord. 2021;22:73. · DOI
  25. Zhang P, Zhu N, Du L, Zheng J, Hu S, Xu B. Treatment of simple bone cysts of the humerus by intramedullary nailing and steroid injection. BMC Musculoskelet Disord. 2020;21:70. · DOI
  26. Omlor GW, Lohnherr V, Lange J, Gantz S, Mechtersheimer G, Merle C, et al. Outcome of conservative and surgical treatment of enchondromas and atypical cartilaginous tumors of the long bones: Retrospective analysis of 228 patients. BMC Musculoskelet Disord. 2019;20:134. · DOI
  27. Gulia A, Kurisunkal V, Puri A, Purandare N, Gupta S, Rangarajan Drm V. VIs skeletal imaging essential in the staging workup for conventional chondrosarcoma? Clin Orthop Relat Res. 2020;478:2480–4. · DOI
  28. Thévenin-Lemoine C, Destombes L, Vial J, Wargny M, Bonnevialle P, Lefevre Y, et al. Planning for bone excision in Ewing sarcoma: Post-chemotherapy MRI more accurate Than pre-chemotherapy MRI assessment. J Bone Joint Surg Am. 2018;100:13–20. · DOI
  29. Andreou D, Ranft A, Gosheger G, Timmermann B, Ladenstein R, Hartmann W, et al. Which factors are associated with local control and survival of patients with localized pelvic Ewing’s sarcoma? A retrospective analysis of data from the euro-EWING99 trial. Clin Orthop Relat Res. 2020;478:290–302. · DOI
  30. Lawrenz JM, Featherall J, Curtis GL, George J, Jin Y, Anderson PM, et al. Time to treatment initiation and survival in adult localized high-grade bone sarcoma. Sarcoma. 2020;2020:2984043. · DOI
  31. Errani C, Ceruso M, Donati DM, Manfrini M. Microsurgical reconstruction with vascularized fibula and massive bone allograft for bone tumors. Eur J Orthop Surg Traumatol. 2019;29:307–11. · DOI
  32. Errani C, Alfaro PA, Ponz V, Colangeli M, Donati DM, Manfrini M. Does the addition of a vascularized fibula improve the results of a massive bone allograft alone for intercalary femur reconstruction of malignant bone tumors in children? Clin Orthop Relat Res. 2021;479:1296–308. · DOI
  33. Tsuda Y, Tsoi K, Stevenson JD, Fujiwara T, Tillman R, Abudu A. Extendable endoprostheses in skeletally immature patients: A study of 124 children surviving more than 10 years After resection of bone sarcomas. J Bone Joint Surg Am. 2020;102:151–62. · DOI
  34. Gupta S, Griffin AM, Gundle K, Kafchinski L, Zarnett O, Ferguson PC, et al. Long-term outcome of iliosacral resection without reconstruction for primary bone tumours. Bone Joint J. 2020;102–B:779–87. · DOI
  35. Jin T, Liu W, Xu H, Li Y, Hao L, Niu X. How does iliosacral bone tumor resection without reconstruction affect the ipsilateral hip joint? BMC Musculoskelet Disord. 2018;19:102. · DOI
  36. Ji T, Yang Y, Tang X, Liang H, Yan T, Yang R, et al. 3D-printed modular hemipelvic endoprosthetic reconstruction following periacetabular tumor resection: Early results of 80 consecutive cases. J Bone Joint Surg Am. 2020;102:1530–41. · DOI
  37. Bosma SE, Cleven AHG, Dijkstra PDS. Can navigation improve the ability to achieve tumor-free margins in pelvic and sacral primary bone sarcoma resections? A historically controlled study. Clin Orthop Relat Res. 2019;477:1548–59. · DOI
  38. Sanders PTJ, Bus MPA, Scheper H, van der Wal RJP, van de Sande MAJ, Bramer JAM, et al. Multiflora and Gram-Negative Microorganisms Predominate in Infections Affecting Pelvic Endoprostheses Following Tumor Resection. J Bone Joint Surg Am. 2019;101:797–803. · DOI
  39. Hirai T, Kobayashi H, Akiyama T, Okuma T, Oka H, Shinoda Y, et al. Predictive factors for complications after surgical treatment for schwannomas of the extremities. BMC Musculoskelet Disord. 2019;20:166. · DOI
  40. Tsukamoto S, Tanzi P, Mavrogenis AF, Akahane M, Kido A, Tanaka Y, et al. Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors. BMC Musculoskelet Disord. 2021;22:12. · DOI
  41. Ruspi L, Cananzi FCM, Sicoli F, Samà L, Renne SL, Marrari A, et al. Event-free survival in Desmoid-Type fibromatosis (DTF): A pre-post comparison of upfront surgery versus wait-and-see approach. Eur J Surg Oncol. 2021;47:1196–200. · DOI
  42. Newman ET, Lans J, Kim J, Ferrone M, Ready J, Schwab J, et al. PROMIS function scores are lower in patients who underwent more aggressive local treatment for desmoid tumors. Clin Orthop Relat Res. 2020;478:563–77. · DOI
  43. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107. · DOI
  44. Kasper B, Raut CP, Gronchi A. Desmoid tumors: To treat or not to treat, that is the question. Cancer. 2020;126:5213–21. · DOI
  45. Improta L, Tzanis D, Bouhadiba T, Abdelhafidh K, Bonvalot S. Desmoid tumours in the surveillance era: What are the remaining indications for surgery? Eur J Surg Oncol. 2020;46:1310–4. · DOI
  46. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109. · DOI
  47. Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379:2417–28. · DOI
  48. Wang Z, Wu J, Tian X, Hao C. Targeted therapy of desmoid-type fibromatosis: Mechanism, current situation, and future prospects. Front Med. 2019;13:427–37. · DOI
  49. Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): A non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019;20:1263–72. · DOI
  50. Kurtz JE, Buy X, Deschamps F, Sauleau E, Bouhamama A, Toulmonde M, et al. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer. 2021;143:78–87. · DOI
  51. Gundle KR, Kafchinski L, Gupta S, Griffin AM, Dickson BC, Chung PW, et al. Analysis of margin classification systems for assessing the risk of local recurrence After soft tissue sarcoma resection. J Clin Oncol. 2018;36:704–9. · DOI
  52. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, et al. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: Retrospective analysis across major histological subtypes and major reference centres. Eur J Cancer. 2018;105:19–27. · DOI
  53. Featherall J, Curtis GL, Lawrenz JM, Jin Y, George J, Scott J, et al. Time to treatment initiation and survival in adult localized, high-grade soft tissue sarcoma. J Surg Oncol. 2019;120:1241–51. · DOI
  54. Paulino Pereira NR, Ogink PT, Groot OQ, Ferrone ML, Hornicek FJ, van Dijk CN, et al. Complications and reoperations after surgery for 647 patients with spine metastatic disease. Spine J. 2019;19:144–56. · DOI
  55. Bindels BJJ, Thio QCBS, Raskin KA, Ferrone ML, Lozano Calderón SA, Schwab JH. Thirty-day postoperative complications After surgery for metastatic long bone disease are associated With higher mortality at 1 year. Clin Orthop Relat Res. 2020;478:306–18. · DOI
  56. Ruatta F, Derosa L, Escudier B, Colomba E, Guida A, Baciarello G, et al. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. Eur J Cancer. 2019;107:79–85. · DOI
  57. Errani C, Mavrogenis AF, Cevolani L, Spinelli S, Piccioli A, Maccauro G, et al. Treatment for long bone metastases based on a systematic literature review. Eur J Orthop Surg Traumatol. 2017;27:205–11. · DOI
  58. Errani C, Cosentino M, Ciani G, Ferra L, Alfaro PA, Bordini B, et al. C-reactive protein and tumour diagnosis predict survival in patients treated surgically for long bone metastases. Int Orthop. 2021;45:1337–46. · DOI
  59. Thio QCBS, Karhade AV, Bindels BJJ, Ogink PT, Bramer JAM, Ferrone ML, et al. Development and internal validation of machine learning algorithms for preoperative survival prediction of extremity metastatic disease. Clin Orthop Relat Res. 2020;478:322–33. · DOI
  60. Philipp TC, Mikula JD, Doung YC, Gundle KR. Is there an association Between prophylactic femur stabilization and survival in patients with metastatic bone disease? Clin Orthop Relat Res. 2020;478:540–6. · DOI
  61. El Abiad JM, Raad M, Puvanesarajah V, Rao SS, Morris CD, Levin AS. Prophylactic versus postfracture stabilization for metastatic lesions of the long bones: a comparison of 30-day postoperative outcomes. J Am Acad Orthop Surg. 2019;27:e709-16. · DOI
  62. Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394:478–87. · DOI
  63. Grünwald V, Karch A, Schuler M, Schöffski P, Kopp HG, Bauer S, et al. Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients With metastatic soft tissue sarcoma age 60 years or older: results of a German intergroup study. J Clin Oncol. 2020;38:3555–64. · DOI
  64. Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups, Spanish, French. J Clin Oncol. 2020;38:2178–86. · DOI
  65. Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4:483–92. · DOI
  66. Chow W, Frankel P, Ruel C, Araujo DM, Milhem M, Okuno S, et al. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. Cancer. 2020;126:105–11. · DOI
  67. Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared With standard chemotherapy in localized high-risk Ewing sarcoma: results of euro-E.W. I. J Clin Oncol. 2018;36(31):JCO2018782516. https://doi.org/10.1200/JCO.2018.78.2516. · DOI
  68. Rajasekaran RB, Whitwell D, Cosker TDA, Gibbons CLMH, Carr A. Will virtual multidisciplinary team meetings become the norm for musculoskeletal oncology care following the COVID-19 pandemic? - Experience from a tertiary sarcoma centre. BMC Musculoskelet Disord. 2021;22:18. · DOI

Cited by

Sorted by citations

Metadata

Authors
Errani, C., Mavrogenis, A. F., & Tsukamoto, S.
Venue
BMC Musculoskeletal Disorders
Publisher
Springer Science and Business Media LLC
Published
2021-08-17
Volume
22
Issue
1
ISSN
1471-2474
DOI
10.1186/s12891-021-04590-1
PMC
PMC8369444
Cited by
11
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review